This brand name is authorized in Ecuador
The drug VIROCOMB-E contains a combination of these active pharmaceutical ingredients (APIs):
|
1
Lamivudine
UNII 2T8Q726O95 - LAMIVUDINE
|
|
Lamivudine is a nucleoside analogue which has activity against human immunodeficiency virus (HIV) and hepatitis B virus (HBV). Its main mode of action is as a chain terminator of viral reverse transcription. |
|
2
Zidovudine
UNII 4B9XT59T7S - ZIDOVUDINE
|
|
Zidovudine is an antiviral agent which is highly active in vitro against retroviruses including the Human Immunodeficiency Virus (HIV). |
|
3
Efavirenz
UNII JE6H2O27P8 - EFAVIRENZ
|
|
Efavirenz is a NNRTI of HIV-1. Efavirenz is a non-competitive inhibitor of HIV-1 reverse transcriptase (RT) and does not significantly inhibit HIV-2 RT or cellular DNA polymerases (α, β, γ or δ). |
This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:
| ATC code | Group title | Classification |
|---|---|---|
| J05AR | Antivirals for treatment of HIV infections, combinations | J Antiinfectives for systemic use → J05 Antivirals for systemic use → J05A Direct acting antivirals |
This drug has been assigned below unique identifiers within the countries it is being marketed:
| Country | Identification scheme | Identifier(s) |
|---|---|---|
| Country: EC | Agencia Nacional de Regulación, Control y Vigilancia Sanitaria | Identifier(s): 27.079-06-06 |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
